Table 1 Clinical and functional characteristics of all the study patients.a,b
From: Redox Imbalance in Lung Cancer of Patients with Underlying Chronic Respiratory Conditions
Anthropometric variables | Controls, N = 17 | LC, N = 21 | LC-COPD, N = 59 | LC-COPD, moderate smokers, N = 24 | LC-COPD, heavy smokers, N = 35 |
|---|---|---|---|---|---|
Age, years | 61 (13) | 63 (12) | 67 (10) | 69 (10) | 66 (10) |
Male/female, N | 8/9 | 14/7 | 57/2 | 23/1 | 34/1 |
BMI, kg/m2 | 26 (3) | 27 (4) | 25 (4) | 25 (4) | 26 (5) |
Smoking history | |||||
Current: N, % | 3, 18 | 11, 52¶¶¶ | 36, 61¶¶¶,** | 11, 46 | 25, 71§§ |
Ex-smoker: N, % | 2, 12 | 6, 29¶¶¶ | 23, 39¶¶¶** | 13, 54 | 10, 29§§ |
Never smoker: N, % | 12, 70 | 4, 19¶¶¶ | 0, 0¶¶¶,** | 0, 0 | 0, 0 |
Pack-years | 35 (19) | 51 (23) | 64 (22)¶,* | 45 (8) | 77 (18)§§§ |
Lung function testing | |||||
FEV1, % predicted | 102 (14) | 91 (9)¶ | 58 (13)¶¶¶,*** | 59 (13) | 56 (13) |
FEV1/FVC, % predicted | 80 (6) | 76 (6) | 61 (8)¶¶¶,*** | 61 (6) | 61 (9) |
DLco, % predicted | 97 (11) | 89 (13) | 68 (18)¶¶¶,*** | 67 (18) | 69 (18) |
Kco, % predicted | 91 (12) | 88 (10) | 79 (20)¶¶,* | 79 (20) | 79 (21) |
TNM staging | |||||
Stage IA: N, % | NA | 5, 24 | 8, 13 | 4, 16 | 4, 11 |
Stage IB: N, % | NA | 1, 5 | 9, 16 | 5, 20 | 4, 11 |
Stage IIA: N, % | NA | 0 | 5, 8 | 1, 5 | 4, 11 |
Stage IIB: N, % | NA | 3, 14 | 2, 3 | 1, 5 | 1, 4 |
Stage IIIA: N, % | NA | 4, 19 | 10, 18 | 3, 12 | 7, 20 |
Stage IIIB: N, % | NA | 4, 19 | 6, 10 | 1, 4 | 5, 14 |
Stage IV: N, % | NA | 4, 19 | 19, 32 | 9, 38 | 10, 29 |
Histological diagnosis | |||||
Squamous cell | NA | 7, 33 | 23, 39 | 10, 42 | 13, 37 |
carcinoma: N, % | |||||
Adenocarcinoma: N, % | NA | 10, 48 | 23, 39 | 9, 37 | 14, 40 |
Others: N, % | NA | 4, 19 | 13, 22 | 5, 21 | 8, 23 |
Blood parameters | |||||
Total leucocytes/µL | 6 × 103 (2.1 × 103) | 9 × 103 (2.1 × 103)¶¶ | 8 × 103 (2.1 × 103)¶¶ | 8 × 103 (2.2 × 103) | 9 × 103 (1.9 × 103) |
Total neutrophils/µL | 4 × 103 (1.9 × 103) | 6 × 103 (2.2 × 103)¶¶ | 6 × 103 (1.7 × 103)¶¶ | 6 × 103 (1.7 × 103) | 6 × 103 (1.7 × 103) |
Total lymphocytes/µL | 2 × 103 (559) | 2 × 103 (622) | 2 × 103 (664) | 1 × 103 (614) | 2 × 103 (660)§ |
Albumin, g/dL | 4.0 (0.4) | 4.3 (0.3) | 4.1 (0.4) | 4.1 (0.4) | 4 (0.4) |
Total proteins, g/dL | 7.2 (0.5) | 7.5 (0.5) | 7.4 (0.5) | 7.3 (0.5) | 7.4 (0.5) |
Fibrinogen, mg/dL | 405 (57) | 474 (97.6) | 445 (148.6) | 419 (148.2) | 469 (148) |
CRP, mg/dL | 0.4 (0.3) | 1.3 (1.3)¶ | 4.8 (6.5)¶¶¶,** | 5.75 (6.6) | 4.1 (6.3) |
GSV, mm/h | 16.1 (11.1) | 20.1 (9.7) | 29.6 (29) | 30 (32) | 29 (27) |
Ceruloplasmin, g/dL | 22.8 (4.6) | 25.7 (4.8) | 30.3 (7.2) | 34 (9) | 29 (5.8) |
Body weight loss, kg | |||||
0: N, % | 0, 0 | 19, 90.4¶¶¶ | 38, 65¶¶¶,*** | 18, 75 | 20, 57§§§ |
1–4: N, % | 0, 0 | 1, 4.8¶¶¶ | 6, 10¶¶¶,*** | 2, 9 | 411§§§ |
5–8: N, % | 1, 100 | 1, 4.8¶¶¶ | 13, 22¶¶¶,*** | 4, 16 | 9, 26§§§ |
9–12: N, % | 0, 0 | 0, 0¶¶¶ | 2, 3¶¶¶,*** | 0, 0 | 2, 6§§§ |